Statement of Changes in Beneficial Ownership (4)
June 18 2020 - 3:06PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
BRATTON DOUGLAS K |
2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc.
[
AQST
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/16/2020 |
(Street)
WARREN, NJ 07059
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | | | | | | | | 75085 | D | |
Common Stock | | | | | | | | 165000 | I | See Footnotes (1)(2)(3) |
Common Stock | | | | | | | | 2249077 | I | See Footnotes (2)(3)(4) |
Common Stock | | | | | | | | 2213314 | I | See Footnotes (2)(3)(5) |
Common Stock | | | | | | | | 4032907 | I | See Footnotes (2)(3)(6) |
Common Stock | | | | | | | | 2755541 | I | See Footnotes (2)(3)(7) |
Common Stock | | | | | | | | 87455 | I | See Footnotes (3)(8) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Purchase) | $5.30 | 6/16/2020 | | A | | 14000 | | 6/16/2021 (9) | 6/16/2030 | Common Stock | 14000 | $0 | 14000 | D | |
Explanation of Responses: |
(1) | These securities are beneficially owned by MonoLine Partners, L.P. ("MonoLine"). |
(2) | These securities are owned, as indicated, by MonoLine, MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities". Bratton Capital Management, L.P. ("Bratton Capital Management") is the general partner of each of the Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by the Monoline Entities. |
(3) | Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. |
(4) | These securities are beneficially owned by MRX Partners. |
(5) | These securities are beneficially owned by Monoline Rx. |
(6) | These securities are beneficially owned by Monoline II. |
(7) | These securities are beneficially owned by Monoline III. |
(8) | These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by Monosol. |
(9) | The shares underlying the options vest as follows: 100% of the underlying shares vest June 16, 2021, subject to Mr. Bratton's continuous service with the Issuer from the grant date through the applicable vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
BRATTON DOUGLAS K C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE WARREN, NJ 07059 | X | X |
|
|
Signatures
|
/s/ Robert Arnold, as Attorney-In-Fact | | 6/18/2020 |
**Signature of Reporting Person | Date |
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From Apr 2024 to May 2024
Aquestive Therapeutics (NASDAQ:AQST)
Historical Stock Chart
From May 2023 to May 2024